🧬 Blocking TGF-β, Boosting Function, Sotatercept's Early Advantage inPAH

🚨 Just out in NEJM! In the Phase 3 HYPERION trial, adding sotatercept early in pulmonary arterial hypertension (PAH) slashed clinical worsening risk by 76% vs placebo (HR 0.24, P   💡 Benefits appeared after just 3 doses, with improved 6-min walk, NT-proBNP, and risk scores. Most AEs were mild (epistaxis, telangiectasia).   📊 A game-changer in early PAH therapy. NNT = 5 over 12 months.   🔗 #Cardiology #PulmonaryHypertension #Sotatercept #NEJM #PrecisionMedicine #ClinicalTrials #RightHeart #TGFb #REVEAL #COMPERA